Keyword: Januvia

8. Janumet

Janumet, which combines Merck’s own blockbuster DPP-4 drug Januvia with metformin, reeled in $984 million in U.S. sales in 2016.
Januvia box

2. Januvia

Merck’s Januvia has faced its share of obstacles, but it remains a mainstay of diabetes treatment—and of Merck’s revenue mix. It brought in $3.91 billion worldwide, $2.29 billion of that in the U.S., and that doesn’t include its combo-med cousin, Janumet.
Diabetes

Top 10 diabetes drugs by 2016 sales

Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward.